2026-04-13T05:50:42Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/708312025-07-05T22:00:04Zcom_2072_6col_2072_452952

2025-07-05T22:00:04Z urn:hdl:10230/70831 SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort Rúa-Figueroa, Iñigo Carrión-Barberà, María Irene Pego-Reigosa, José Maria Epidemiology Lupus erythematosus Systemic Risk factors Objective: To develop an improved score for prediction of severe infection in patients with systemic lupus erythematosus (SLE), namely, the SLE Severe Infection Score-Revised (SLESIS-R) and to validate it in a large multicentre lupus cohort. Methods: We used data from the prospective phase of RELESSER (RELESSER-PROS), the SLE register of the Spanish Society of Rheumatology. A multivariable logistic model was constructed taking into account the variables already forming the SLESIS score, plus all other potential predictors identified in a literature review. Performance was analysed using the C-statistic and the area under the receiver operating characteristic curve (AUROC). Internal validation was carried out using a 100-sample bootstrapping procedure. ORs were transformed into score items, and the AUROC was used to determine performance. Results: A total of 1459 patients who had completed 1 year of follow-up were included in the development cohort (mean age, 49±13 years; 90% women). Twenty-five (1.7%) had experienced ≥1 severe infection. According to the adjusted multivariate model, severe infection could be predicted from four variables: age (years) ≥60, previous SLE-related hospitalisation, previous serious infection and glucocorticoid dose. A score was built from the best model, taking values from 0 to 17. The AUROC was 0.861 (0.777-0.946). The cut-off chosen was ≥6, which exhibited an accuracy of 85.9% and a positive likelihood ratio of 5.48. Conclusions: SLESIS-R is an accurate and feasible instrument for predicting infections in patients with SLE. SLESIS-R could help to make informed decisions on the use of immunosuppressants and the implementation of preventive measures. 2025-07-05T22:00:04Z 2025-07-05T22:00:04Z 2025-07-04T06:26:12Z 2025-07-04T06:26:12Z 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/10230/70831 Lupus Sci Med. 2024 Apr 8;11(1):e001096 © 2024, The Author(s). Published by BMJ Publishing Group Ltd. This article is available under the Creative Commons CC-BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0) and permits non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by-nc/4.0 info:eu-repo/semantics/openAccess BMJ Publishing Group